Catalog No.
DHC09609
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
p185erbB2, HER2, NGL, Tyrosine kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19, ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, ERBB3, HER3, Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, Receptor tyrosine-protein kinase erbB-3
Concentration
1.75 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P04626 & P21860
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, MCLA-128, PB4188, R040517, CAS: 1969309-56-5
Clone ID
Zenocutuzumab
Zenocutuzumab Shines in PDAC, PMID: 34112697
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade, PMID: 29763625
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose, PMID: 29728897
NRG1 fusions: Biology to therapy, PMID: 34098222
The Exciting New Field of HER2-Low Breast Cancer Treatment, PMID: 33804398
A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G 1, PMID: 28655766
Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration., PMID:40397846
eNRGy: Making progress toward a future for NRG1 fusion-positive cancer., PMID:40220746
Emerging importance of HER3 in tumorigenesis and cancer therapy., PMID:40087402
Zenocutuzumab: First Approval., PMID:39994106
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours., PMID:39979643
Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review., PMID:39971274
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer., PMID:39908431
NRG1 Fusions: The New Kid on the Block., PMID:39888568
The use of zenocutuzumab for NRG1 fusion-positive tumors., PMID:39820371
Zenocutuzumab (Bizengri) for NSCLC and pancreatic adenocarcinoma., PMID:39819990
Antibodies to watch in 2025., PMID:39711140
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions., PMID:38348690
Antibodies to watch in 2024., PMID:38178784
Profiling of gene fusion involving targetable genes in Chinese gastric cancer., PMID:36160735
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)., PMID:36107417
Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor., PMID:35977350
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements., PMID:35135829
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines., PMID:35035535
[Not Available]., PMID:34969512
Zenocutuzumab Shines in PDAC., PMID:34112697
NRG1 fusions: Biology to therapy., PMID:34098222
The Exciting New Field of HER2-Low Breast Cancer Treatment., PMID:33804398
Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors., PMID:32006223
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade., PMID:29763625
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose., PMID:29728897
A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1., PMID:28655766
For research use only. Not for human or drug use.
